LoQus23 Therapeutics

LoQus23 Therapeutics is discovering oral small molecule therapies targeting abnormal DNA mismatch repair to effectively treat Huntington's disease and other triplet repeat disorders. Our expert team is taking a structure-based approach to discover mismatch repair drugs, researching small molecule drugs that can prevent DNA instability, thereby slowing neurodegeneration in Huntington's disease, myotonic dystrophy type 1, and similar triplet repeat expansion disorders. Oral small molecule drugs have a strong track record in treating complex brain diseases, offering greater convenience to patients compared to other treatment methods.